Anna Raciborska clinical trial pipeline

3 trials changed in the last 30 days: 0 stopped, 0 with notable changes, 3 with minor changes only.

1. Minor

   HISTIOGEN · Determination of Molecular Status, the Efficacy and…HISTIOGEN · Determination of Molecular Status, the Efficacy and Safety of Fluorodeoxyglucose in PET-CT Imaging

   Enrollment closed, study ongoing

   Anna Raciborska·Phase 3· NCT04943211· Registry history of NCT04943211 on ClinicalTrials.gov (opens the registry)

   Updated Oct 7, 2026

2. Minor

   TRAM · Optimization of the Time and Dosage of Trametinib in BRAF…TRAM · Optimization of the Time and Dosage of Trametinib in BRAF Negative Juvenile Patients

   Enrollment closed, study ongoing

   Anna Raciborska·Phase 2· NCT04943224· Registry history of NCT04943224 on ClinicalTrials.gov (opens the registry)

   Updated Oct 7, 2026

3. Minor

   BRAVO · Optimization of the Time and Dosage of Vemurafenib in…BRAVO · Optimization of the Time and Dosage of Vemurafenib in BRAF Positive Juvenile · Refractory Histiocytosis

   Enrollment closed, study ongoing

   Anna Raciborska·Phase 2· NCT04943198· Registry history of NCT04943198 on ClinicalTrials.gov (opens the registry)

   Updated Oct 7, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.